genedrive plc to Present at the UK Investor Show

RNS Number : 2462L

Genedrive PLC

18 April 2018

 

For release RNS Reach: 18 April 2018

genedrive plc ("genedrive" or the "Company")

genedrive plc to Present at the UK Investor Show

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces that David Budd, CEO and Matthew Fowler, CFO, will be attending the UK Investor Show, Britain's largest one day investor event.

The event will take place on Saturday 21^st April 2018 at the Queen Elizabeth II Conference Centre in Westminster, London. The Company will be based at stand 72 from 8.30am until 5.30pm to discuss genedrive's recent progress and growth strategy with existing and prospective investors.

For more details on the event please visit: www.ukinvestorshow.com

-  Ends  -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                   [phone]

Matthew Fowler: CFO

Peel Hunt LLP

James Steel                                                                                                            [phone]

Oliver Jackson

Stanford Capital Partners Limited                                                                    [phone]

Patrick Claridge

Consilium Strategic Communications

Chris Gardner                                                                                                        [phone]

Matthew Neal

Laura Thornton

[e-mail] 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA  and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV ID Kit and Genedrive® platform in India.

Further details can be found at: www.genedriveplc.com and www.genedrive.com

 

END

 

 

NRAUBAARWAASAUR